QUALITATIVE AND QUANTITATIVE COMPOSITION
Each 1 ml contains:
Flunixin (Equivalent to 82.88 mg Flunixin Meglumine) ……50 mg
PROPERTIES AND THERAPEUTIC INDICATIONS:
Dolorixin is recommended for the alleviation of visceral pain and inflammation in colicky conditions and different musculoskeletal disorders in horses, reduces pain and pyrexia caused by different infectious diseases in bovine especially Bovine Respiratory Disease as well as endotoxemia in various conditions including genital infections.
Among the Non-Steroidal Anti-Inflammatory Drugs, Flunixin Meglumine is considered to be of the most potent; it has analgesic, anti-inflammatory and antipyretic activity. It is significantly more potent than pentazocine, meperidine, and codeine.
Following a single dose of 1.1 mg/kg the plasma half-life in horse serum is 1.6 hours. It was still detectable in horse plasma 8 hours post injection.
MODE OF ACTION :
Flunixin meglumine, like other non-steroidal anti-inflammatory drugs, acts by inhibiting cyclo-oxygenase mediated production of prostaglandins PGE2. It has analgesic, antipyretic and slight anti-inflammatory properties. Its potency is four times more than that of phenylbutazone in its ability to reduce lameness and swelling in the horse.
DOSES AND METHOD OF ADMINISTRATION :
Horse: 0.5-1.1 mg/kg body weight (0.45-1 ml per 45 kg) by Intravenous or Intramuscular route.
For musculoskeletal disorders the recommended dose is 1.1 mg per kg body weight (1 ml of Dolorixin per 45 kg) once daily. Treatment may be given by intravenous or intramuscular injection and repeated for up to 5 days. Studies show that peak response occurs between 12 and 16 hours and duration of activity is 24-36 hours. The recommended dose for the alleviation of pain associated with equine colic is 1.1 mg per kg of body weight. Intravenous administration is recommended for prompt relief.
Cattle: 1.1-2.2 mg/kg/day body weight (1-2 ml per 45 kg per day), given by slow intravenous route is recommended. To be given either once a day as a single dose or divided into two doses administered at 12-hour difference for up to 3 days. The total daily dose should not exceed 2.2 mg/kg (1.0 mg/lb) of body weight.
Do not use in animals showing hypersensitivity to flunixin meglumine.
In rare cases, animals may show anaphylactic-like reactions.
Not for use in lactating and dry cows, veal calves as well as breeding bulls
Intra-arterial injection should be avoided; transient signs such as ataxia, incoordination, hyperventilation, hysteria, and muscle weakness may appear few minutes.
Avoid rapid intravenous administration of the drug.
Cattle must not be slaughtered for human consumption within 7 days of the last treatment.
Isolated reports of localized swelling, induration, sweating, and stiffness following flunixin use. In addition, rare instances of anaphylactic-like reactions have been reported primarily following intravenous use.
PHARMACEUTICAL FORM AND PACKAGE FORM:
50 mg/ml injectable solution in 20, 50 and 100 ml amber glass bottles.
Store in a dark place at a temperature below 30º C.
FOR VETERINARY USE ONLY